ProVise Management Group, LLC - CATALYST PHARMACEUTICALS INC ownership

CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 145 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 1.85 and the average weighting 0.0%.

Quarter-by-quarter ownership
ProVise Management Group, LLC ownership history of CATALYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2022$98,000
-38.0%
14,000
-26.3%
0.01%
-33.3%
Q1 2022$158,000
+22.5%
19,0000.0%0.02%
+25.0%
Q4 2021$129,000
+27.7%
19,0000.0%0.01%
+20.0%
Q3 2021$101,000
-7.3%
19,0000.0%0.01%
-9.1%
Q2 2021$109,000
+23.9%
19,0000.0%0.01%
+22.2%
Q1 2021$88,000
+39.7%
19,0000.0%0.01%
+28.6%
Q4 2020$63,000
+12.5%
19,0000.0%0.01%0.0%
Q3 2020$56,000
-36.4%
19,0000.0%0.01%
-46.2%
Q2 2020$88,000
+20.5%
19,0000.0%0.01%
+8.3%
Q1 2020$73,000
+2.8%
19,0000.0%0.01%
+33.3%
Q4 2019$71,000
-29.7%
19,0000.0%0.01%
-30.8%
Q3 2019$101,000
+38.4%
19,0000.0%0.01%
+30.0%
Q2 2019$73,000
-24.7%
19,0000.0%0.01%
-28.6%
Q1 2019$97,000
+169.4%
19,0000.0%0.01%
+133.3%
Q4 2018$36,000
-50.0%
19,0000.0%0.01%
-33.3%
Q3 2018$72,000
+22.0%
19,0000.0%0.01%
+125.0%
Q2 2018$59,000
+31.1%
19,0000.0%0.00%
-42.9%
Q1 2018$45,000
-39.2%
19,0000.0%0.01%
-36.4%
Q4 2017$74,000
+54.2%
19,0000.0%0.01%
+57.1%
Q3 2017$48,000
-7.7%
19,0000.0%0.01%
-12.5%
Q2 2017$52,000
+40.5%
19,0000.0%0.01%
+33.3%
Q1 2017$37,000
+85.0%
19,0000.0%0.01%
+100.0%
Q4 2016$20,000
-4.8%
19,0000.0%0.00%
-25.0%
Q3 2016$21,000
+61.5%
19,0000.0%0.00%
+100.0%
Q2 2016$13,00019,0000.00%
Other shareholders
CATALYST PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
Opaleye Management Inc. 1,378,584$3,116,0002.30%
TANAKA CAPITAL MANAGEMENT INC 147,993$298,0000.90%
SOPHROSYNE CAPITAL LLC 282,500$638,0000.56%
Ghost Tree Capital, LLC 200,000$452,0000.27%
Orbimed Advisors 1,895,000$4,283,0000.05%
Financial Architects, Inc 30,000$68,0000.04%
Cowen Prime Services LLC 43,550$98,0000.04%
Rotella Capital Management, Inc. 12,300$28,0000.03%
FEDERATED HERMES, INC. 3,267,000$7,384,0000.02%
Baker Brothers Advisors 569,853$1,288,0000.02%
View complete list of CATALYST PHARMACEUTICALS INC shareholders